FY2025 EPS Estimates for Galectin Therapeutics Inc. Lowered by Analyst (NASDAQ:GALT)Zolmax • 24 days ago
Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Research analysts at HC Wainwright lowered their FY2025 EPS estimates for shares of Galectin Therapeutics in a report released on Monday...
Share to Feed
Retirement Guys Formula LLC grew its stake in shares of Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 87.0% during the fourth quarter, according to the company in its most recent 13F...
Galectin Therapeutics (NASDAQ:GALT - Get Free Report)s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They...
Galectin Therapeutics GAAP EPS of -$0.74...
NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results...
Comparing GALT's Performance Against Analyst Estimates and Exploring Future ProspectsRelated Stocks: GALT...
StockNews.com downgraded shares of Galectin Therapeutics (NASDAQ:GALT Free Report) from a hold rating to a sell rating in a research report report published on Monday. Galectin Therapeutics...
NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of...
Galectin Therapeutics (NASDAQ:GALT Get Free Report) and Xilio Therapeutics (NASDAQ:XLO Get Free Report) are both small-cap medical companies, but which is the superior investment? We...
AE Wealth Management LLC grew its holdings in shares of Galectin Therapeutics Inc. (NASDAQ:GALT Free Report) by 72.7% in the 3rd quarter, according to the company in its most recent...